Home > Rheumatology > Adding methotrexate to pegloticase nearly doubles gout response rate

Adding methotrexate to pegloticase nearly doubles gout response rate

Expert
Dr John K Botson, Orthopedic Physicians Alaska, Anchorage
Conference
ACR 2021
Trial
Phase 3, MIRROR RCT
MIRROR RCT (NCT03994731) phase III data support the combination of immunosuppression with pegloticase treatment for uncontrolled gout in all patients, raising the response rate from 40-42% to 71%. Medicom spoke with Dr John K Botson, (Orthopedic Physicians Alaska, Anchorage), which was highlighted at the annual American College of Rheumatology Convergence of 2021, which was held from 3 to 10 November. Medicom: How did you think about combining immunomodulation agents to improve response with pegloticase?  “This i...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on